Evidence map›Paper›PMID 29805095›Full record

ArticleCell host & microbe2018

Genomic Epidemiology Reconstructs the Introduction and Spread of Zika Virus in Central America and Mexico.

Julien Thézé, Tony Li, Louis du Plessis, Jerome Bouquet, Moritz U G Kraemer, Sneha Somasekar, Guixia Yu, Mariateresa de Cesare, Angel Balmaseda, Guillermina Kuan and 19 more

Abstract read
In one paragraph

Article in Cell host & microbe, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Julien ThézéDepartment of Zoology, University of Oxford, Oxford, UK.
Tony LiDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.
Louis du PlessisDepartment of Zoology, University of Oxford, Oxford, UK.
Jerome BouquetDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.
Moritz U G KraemerDepartment of Zoology, University of Oxford, Oxford, UK; Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Harvard University, Boston, MA, USA.
Sneha SomasekarDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.
Guixia YuDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.
Mariateresa de CesareOxford Genomics Centre, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
Angel BalmasedaLaboratory Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministerio de Salud, Managua, Nicaragua.
Guillermina KuanCentro de Salud Sócrates Flores Vivas, Ministerio de Salud, Managua, Nicaragua.
Eva HarrisDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, CA, USA.
Chieh-Hsi WuDepartment of Statistics, University of Oxford, Oxford, UK.
M Azim AnsariOxford Genomics Centre, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Rory BowdenOxford Genomics Centre, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
Nuno R FariaDepartment of Zoology, University of Oxford, Oxford, UK.
Shigeo YagiCalifornia Department of Public Health, Richmond, CA, USA.
Sharon MessengerCalifornia Department of Public Health, Richmond, CA, USA.
Trevor BrooksBlood Systems Research Institute, San Francisco, CA, USA.
Mars StoneBlood Systems Research Institute, San Francisco, CA, USA.
Evan M BlochDepartment of Pathology, Johns Hopkins University School of Medcine, Baltimore, MD, USA.
Michael BuschBlood Systems Research Institute, San Francisco, CA, USA.
José E Muñoz-MedinaDivisión de Laboratorios de Vigilancia e Investigación Epidemiológica, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Cesar R González-BonillaDivisión de Laboratorios de Vigilancia e Investigación Epidemiológica, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Steven WolinskyDivision of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Susana LópezInstituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Mexico.
Carlos F AriasInstituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Mexico.
David BonsallNuffield Department of Medicine, University of Oxford, Oxford, UK.
Charles Y ChiuDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA; Department of Medicine, Division of Infectious Diseases, University of California, San Francisco, CA, USA. Electronic address: charles.chiu@ucsf.edu.
Oliver G PybusDepartment of Zoology, University of Oxford, Oxford, UK. Electronic address: oliver.pybus@zoo.ox.ac.uk.

Funding

Project 3 - Ex vivo immune profiling of dengue viruses and vaccinesU19AI118610 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HARRIS, EVA · 2015 to 2021
$46.6M
T Cell Responses Following DENV Natural Infections and Live-Attenuated Dengue Virus VaccinationP01AI106695 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI Aravinda M. DeSilva · 2015 to 2026
$34.1M
Viral Immunity and VAccination (VIVA) Human Immunology Project Consortium (HIPC)U19AI168631 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Harm van Bakel · 2022 to 2026
$14.4M
Pan-Genomic Approaches for Comprehensive Blood Screening of Novel or Emerging Infectious AgentsR01HL105704 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHIU, CHARLES YEN · 2011 to 2020
$5.9M
RESEARCH TRAINING IN PEDIATRIC EMERGENCY MEDICINET32HD040128 · NICHD · CHILDREN'S HOSPITAL BOSTON · PI Kenneth D. Mandl · 2001 to 2026
$5.0M
A Platform for Modeling the Global Impact of Climate Change on Infectious DiseaseR01LM010812 · NLM · BOSTON CHILDREN'S HOSPITAL · PI BROWNSTEIN, JOHN S. · 2010 to 2015
$2.5M
Epidemiological, Clinical & Immunological Studies of Zika, dengue and chikungunyaR01AI099631 · NIAID · SUSTAINABLE SCIENCES INSTITUTE · PI BALMASEDA, ANGEL LAZARO · 2012 to 2021
$1.8M
Real-Time Unbiased Pathogen Detection in Febrile Illnesses by Nanopore SequencingR33AI120977 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHIU, CHARLES YEN · 2018 to 2020
$1.6M
An Approach for Estimating Foodborne Illnesses and Assessing Risk FactorsR01LM011965 · NLM · BOSTON CHILDREN'S HOSPITAL · PI BROWNSTEIN, JOHN S., NSOESIE, ELAINE O. · 2015 to 2018
$1.4M
Identification of diagnostic and prognostic host biomarkers of Zika virus infection by transcriptome profilingR21AI129455 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHIU, CHARLES YEN · 2017 to 2018
$436k
Real-Time Unbiased Pathogen Detection in Febrile Illnesses by Nanopore SequencingR21AI120977 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHIU, CHARLES YEN · 2016 to 2017
$436k
NHLBI NIH HHS R01 HL105704NIAID NIH HHS P01 AI106695NIAID NIH HHS R01 AI099631NIAID NIH HHS R21 AI120977NIAID NIH HHS R21 AI129455NIAID NIH HHS R33 AI120977NIAID NIH HHS U19 AI118610NIAID NIH HHS U19 AI168631NICHD NIH HHS T32 HD040128NLM NIH HHS R01 LM010812NLM NIH HHS R01 LM011965Wellcome Trust
6 · The paper itself

Abstract

The Zika virus (ZIKV) epidemic in the Americas established ZIKV as a major public health threat and uncovered its association with severe diseases, including microcephaly. However, genetic epidemiology in some at-risk regions, particularly Central America and Mexico, remains limited. We report 61 ZIKV genomes from this region, generated using metagenomic sequencing with ZIKV-specific enrichment, and combine phylogenetic, epidemiological, and environmental data to reconstruct ZIKV transmission. These analyses revealed multiple independent ZIKV introductions to Central America and Mexico. One introduction, likely from Brazil via Honduras, led to most infections and the undetected spread of ZIKV through the region from late 2014. Multiple lines of evidence indicate biannual peaks of ZIKV transmission in the region, likely driven by varying local environmental conditions for mosquito vectors and herd immunity. The spatial and temporal heterogeneity of ZIKV transmission in Central America and Mexico challenges arbovirus surveillance and disease control measures.

Indexed as

AdolescentAdultBrazilCentral AmericaChildChild, PreschoolGenome, ViralHumansImmunity, HerdMetagenomicsMexicoMosquito VectorsPhylogenySequence Analysis, RNAZika VirusZika Virus Infectionbait capture enrichmentCentral Americaeffective reproductive numbergenomicsmetagenomic sequencingMexicophylodynamics“spiked” primer enrichmenttransmissionZika virus

Identifiers

PMID29805095
PMCPMC6006413

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.